Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.19
- Piotroski Score 4.00
- Grade Neutral
- Symbol (ZYME)
- Company Zymeworks Inc.
- Price $13.19
- Changes Percentage (2.73%)
- Change $0.35
- Day Low $12.61
- Day High $13.23
- Year High $13.27
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $12.00
- High Stock Price Target $21.00
- Low Stock Price Target $11.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.78
- Trailing P/E Ratio -5.1
- Forward P/E Ratio -5.1
- P/E Growth -5.1
- Net Income $-118,674,000
Income Statement
Quarterly
Annual
Latest News of ZYME
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
ArcticZymes Technologies ASA (FRA:B4V) Q2 2024 Earnings Call Highlights: Record Orders and ...
The CEO discusses evaluation orders, CDMO supply agreement, nucleases usage, strategic priorities, and regulatory compliance in the earnings call. ArcticZymes aims to enhance sales, partnerships, and ...
By Yahoo! Finance | 3 days ago -
Halozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History - Yahoo Finance
Roche has gained FDA approval for OCREVUS ZUNOVO™, a treatment for multiple sclerosis using Halozyme's ENHANZE® drug delivery technology. The medication is administered as a subcutaneous injection ...
By Yahoo! Finance | 3 weeks ago -
FDA approves Roche's Ocrevus Zunovo with Halozyme Enhanze delivery tech
Roche's Ocrevus Zunovo, utilizing Halozyme's Enhanze technology, received FDA approval for subcutaneous injection to treat multiple sclerosis. The new method offers flexibility and efficiency, with co...
By Yahoo! Finance | 3 weeks ago
